THE POTENTIAL FOR IMMUNOCONJUGATES IN LYMPHOMA THERAPY
- 1 October 1997
- journal article
- review article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 11 (5) , 987-1006
- https://doi.org/10.1016/s0889-8588(05)70475-5
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Radioimmunotherapy of Lymphoma: A UC Davis ExperienceHybridoma, 1995
- Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibodyCancer Immunology, Immunotherapy, 1991
- A phase 1a clinical trial of LYM‐1 monoclonal antibody serotherapy in patients with refractory b cell malignanciesHematological Oncology, 1989
- An anti‐CD5 immunotoxin for chronic lymphocytic leukemia: Enhancement of cytotoxicity with human serum albumin‐monensinInternational Journal of Cancer, 1989
- Reshaping human antibodies for therapyNature, 1988
- Targeting of Cytotoxic Cells with Heterocrosslinked AntibodiesCancer Investigation, 1988
- High-Dose Therapy and Autologous Bone Marrow Transplantation after Failure of Conventional Chemotherapy in Adults with Intermediate-Grade or High-Grade Non-Hodgkin's LymphomaNew England Journal of Medicine, 1987
- Replacing the complementarity-determining regions in a human antibody with those from a mouseNature, 1986
- Emergence of Idiotype Variants during Treatment of B-Cell Lymphoma with Anti-Idiotype AntibodiesNew England Journal of Medicine, 1985
- Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype AntibodyNew England Journal of Medicine, 1982